Poolbeg Pharma (POLB), a clinical-stage infectious disease pharmaceutical company, said that AI partner OneThree Biotech, Inc., has completed the build and optimisation of a tailored AI model of Poolbeg’s RSV human challenge data and can now commence its analysis, with results expected in Q4 2022.
Poolbeg said OneThree Biotech’s AI model optimisation has been completed on time and is on track to deliver results later this year. This is the first time that AI has been used to model RSV with the complete longitudinal disease data which can only be produced from human challenge trials.
Nuformix (NFX), a pharmaceutical development company, updated in relation to its NXP002 asset, a new form of tranilast and a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis. The company said that after the frustrations of the study undertaken earlier this year from which no conclusions could be drawn, it is back on track to investigate the product opportunity further.
Pires Investments (PIRI), the investment company, updated on developments relating to companies within its investment portfolio, through its investment in Sure Valley Ventures. The company said that Admix combining with LandVault presents an “excellent opportunity” for the company to enter into Web3 and provide a go-to offering for major brands looking to capitalise on the metaverse. The launch of Low6’s new B2B white-label gamification platform enables the business to further increase the reach of its iGaming products to some of the largest names in sports, gaming, media and mobile technology. ENGAGE XR’s latest announcement demonstrates the continued developments at an “exciting” time for the business.
Oracle Power (ORCP), the international natural resources project developer, has signed a non-binding MoU with Nuvera Fuel Cells LLC to jointly explore opportunities for de-carbonised heavy-duty transport and port infrastructure in Pakistan powered by green hydrogen. Nuvera, headquartered in Massachusetts, is enabling hydrogen vehicle adoption.
Arrow Exploration (AXL) announced the results of the Rio Cravo Sur-1 well testing on the Tapir Block in the Llanos Basin of Colombia. The RCS-1 well was spud on May 23, 2022. RCS-1 targeted a three-way fault bounded structure with multiple high-quality reservoir objectives on the Tapir Block in the Llanos Basin of Colombia. The well was drilled to a total measured depth of 8,656 feet (8,105 feet true vertical depth) and encountered six hydrocarbon bearing intervals totaling 55 net feet of oil pay.
Belluscura (BELL), a medical device developer announced the launch of its Bluetooth® enabled, next generation X-PLOR® portable oxygen concentrator.The next generation X-PLOR provides more oxygen by weight than any portable oxygen concentrator in its class and with its new Nomad Health™ App, patients can connect other Bluetooth® devices such as their iPhone® or Android phone, Nonin® or Masimo® pulse oximeters, and Fitbit® wearables.
Mosman Oil and Gas (MSMN) the oil exploration and production company, provided an operations update. Production for the three months ending 31 March 2022 was 22,409 boe (Gross), 11,756 boe (Net attributable to Mosman). Final June quarter numbers will be announced in late July and in the interim Mosman advised the preliminary numbers for the two months ending 31 May 2022 are: 15,682 boe (Gross), 6,276 boe (net attributable to Mosman).
Versarien (VRS), the advanced engineering materials group, announced the launch of a new hybrid nanomaterial that has superparamagnetic properties, which can be used across a range of applications, such as in defence and healthcare. The development of the material has been led by Versarien’s 62% owned subsidiary, Gnanomat S.L.
Eco (Atlantic) Oil & Gas (ECO), the oil and gas exploration company, announced the completion of an equity fundraise of $12.3m. The company said it was able to include some of the leading South African focussed funds in this financing, thus supporting the regional efforts to become energy independent and to promote the local partners and oil and gas exploration efforts in South Africa.
Hemogenyx Pharmaceuticals (HEMO) announced that Dr Vladislav Sandler, Chief Executive Officer & Co-Founder of Hemogenyx Pharmaceuticals, will host a live investor webinar on 6 July 2022 at 16:00 BST at which he will present an overview of the Company’s activities and immediate future directions of its work.
Powerhouse Energy Group (PHE), the UK technology company commercialising hydrogen production from plastic, confirms the appointment of Keith Riley as Interim Chairman. Keith Riley is currently a Non-executive Director on the Board and will assume responsibilities as Interim Non-executive Chairman with immediate effect.
ANGLE (AGL), a liquid biopsy company, announced research by the team at the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland. The study utilised the Parsortix® system to investigate the impact of sleep on the release of CTCs in preclinical models and 30 patients with breast cancer (21 with early stage and 9 with metastatic disease). ANGLE said that Metastasis is responsible for 90% of cancer patient deaths so these findings mark a significant development in the understanding of cancer progression and provide novel insight for drug discovery.
Genflow (GENF) has entered into a research agreement with Magnitude Biosciences Limited, a UK-based, specialist biotechnology research organisation that supports drug discovery and product development. Genflow said this collaboration gives it the opportunity to work with a company that has tremendous experience in longevity and has a uniquely skilled team. Through this collaboration, Genflow’s future therapeutic developments will be accelerated by Magnitude’s innovative technology which has the capacity to significantly expedite product development, supported by sophisticated machine monitoring.
MGC Pharmaceuticals (MXC) a European-based bio-pharma company, updated on its pre-clinical In vitro study into CimetrATM, MGC Pharma’s proprietary Investigation Medicinal Product (IMP), mechanism of action in inhibiting cytokine production. Results from the study indicate that CimetrATM may have a wider-ranging application as an anti-inflammatory treatment, which has been the primary focus of clinical trials to date, and which are continuing to be progressed.
Bens Creek Group (BEN), the owner of a metallurgical coal mine in North America, announced that it has now exercised its right of first refusal on a further highwall miner and related equipment to be supplied by MHW. Whilst the Company’s request to MHW has been accepted, it is anticipated the formal agreement with MHW for the supply of a second highwall miner will be completed during July 2022 on similar terms as the initial highwall miner supplied by MHW, including a production target of between 32,000 and 40,000 tons of metallurgical coal per month.
Redx (REDX), the clinical-stage biotechnology company, announced that two presentations were delivered at the inaugural Extracellular Matrix Pharmacology Congress in Copenhagen, 23-25 June. The presentations highlighted novel preclinical research performed by the company and academic collaborators including encouraging data supporting Redx’s Porcupine and ROCK inhibitors as potential novel treatments for cancer-associated fibrosis.
Challenger Energy (CEG), the Caribbean and Atlantic-margin focused oil and gas company, noted recent commentary on the recent Uruguay licensing round and in relation to its AREA OFF-1 petroleum licence offshore Uruguay. The company said it considers the entry into Uruguay of two well regarded international companies such as Shell and APA Corp, and the commitment by both to undertake sizeable and meaningful work programs during an initial exploration period (including 3D seismic acquisition and new well drilling), to be a highly positive development.
ImmuPharma (IMM), the specialist drug discovery and development company, announced that, having met all the FDA requirements, Avion Pharmaceuticals, its US partner, has confirmed that it has sought final regulatory guidance from the FDA, as it actively prepares for the start of the international Phase 3 trial of Lupuzor™ in Lupus patients.
Savannah Energy (SAV), the British independent energy company, announced that Accugas Limited, the Company’s 80% indirectly owned subsidiary, has commenced gas sales to Central Horizon Gas Company Limited, a subsidiary of Axxela Limited, and a major gas distribution company situated in the South-South region of Nigeria.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned